



Atty. Dkt. No. 074129-0521

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Kouhei TOYOOKA, et al.

Title: ISOINDOLINE DERIVATIVES

Appl. No.: 10/534,414

International 11/25/2003

Filing Date:

371(c) Date: 05/11/2005

Examiner: Jarrell, Noble E.

Art Unit: 1624

Confirmation 7101

Number:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56.

A copy of each non-U.S. patent document and each non-patent document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being cited in compliance with 37 CFR §1.97(c), before the mailing date of either a final action under 37 CFR §1.113, a notice of allowance under 37 CFR §1.311, or an action that otherwise closes prosecution in the application.

RELEVANCE OF EACH DOCUMENT

Documents C1-C3 listed on the attached PTO/SB/08 were previously cited in Applicants' Information Disclosure Statement filed on February 23, 2007. Copies of these documents were submitted to the U.S. Patent and Trademark Office with the February 23, 2007 Information Disclosure Statement.

Applicants provide the following concise statements of relevance, as disclosed in the present specification:

Documents C1 and C3, Japanese Patent Application Laid-Open Nos. JP 47-12322 and JP 58-189163, appear to disclose, respectively, compounds having an isoindoline structure that have been reported to have effects on the central nervous system, for use in developing tranquilizers and anticonvulsants, and 2,6-diisopropylphenol compositions for producing anaesthesia. U.S. Pat. No. 3,818,011 (cited as Document B1 in Applicants' Information Disclosure Statement filed on February 23, 2007) is believed to be the U.S. counterpart of Document C1. U.S. Pat. Nos. 4,056,635 and 4,452,817 (cited as Document B2 and Document B3, respectively, in Applicants' Information Disclosure Statement filed on February 23, 2007) are believed to be the U.S. counterparts of Document C3.

Document C2, Japanese Patent Application Laid-Open No. JP 50-154410, appears to disclose condensed pyrrolinone derivatives having antianxiety effects, and the therapeutic index values for the clinically used intravenous anesthetics propofol and thiopental sodium, cited for the purposes of comparison in Table 10 of Example 31 of the present specification. U.S. Pat. No. 4,590,189 (cited as Document B4 in Applicants' Information Disclosure Statement filed on February 23, 2007) is believed to be the U.S. counterpart of Document C2.

Documents C4-C7 listed on the attached PTO/SB/08 were previously cited in Applicants' Information Disclosure Statement filed on May 11, 2005. Copies of documents C4-C7 are attached herewith.

Applicants respectfully request that each listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

FEE

As a courtesy, attached please find copies of the references cited but not considered in the Information Disclosure Statements filed on May 11, 2005, and February 23, 2007. As the subject application is the US National phase of PCT/JP03/14986, the references were assumed to have been provided by WIPO and are being supplied for consideration herewith.

In reference to the above paragraph we do not believe a fee is due. However, if a fee is due, please charge Deposit Account No. 19-0741 in the amount of \$180.00 in accordance with 37 CFR §1.17(p) to cover the fee associated with a supplemental information disclosure statement under 37 CFR §1.97(c). A duplicate copy of this transmittal is enclosed.

Respectfully submitted,

Date February 25, 2008

By Ann E. Summerfield

FOLEY & LARDNER LLP
Customer Number: 22428
Telephone: (202) 672-5571
Facsimile: (202) 672-5399

Ann E. Summerfield
Attorney for Applicants
Registration No. 47,982